Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images
March 30, 2021 05:20 PM EDTUpdated April 2, 12:11 PM
Deals
FDA+

Look­ing to crack down on big bio­phar­ma M&A deals, FTC sues to block Il­lu­mi­na's $8B Grail ac­qui­si­tion

Jason Mast

Editor

For the sec­ond time in as many years, the FTC is try­ing to block Il­lu­mi­na from mak­ing a mul­ti-bil­lion dol­lar ac­qui­si­tion.

The fed­er­al agency filed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times